MGMT and glioblastoma: For instance, the development of the integrin antagonist cilengitide was halted when a phase III trial failed to show that the addition of cilengitide to temozolomide chemoradiotherapy was of any benefit in patients with newly diagnosed glioblastoma and MGMT promoter methylation [42].